327 related articles for article (PubMed ID: 27461144)
21. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits.
Villani A; Cinelli E; Fabbrocini G; Lallas A; Scalvenzi M
Expert Opin Drug Saf; 2020 Dec; 19(12):1585-1594. PubMed ID: 33054455
[TBL] [Abstract][Full Text] [Related]
22. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
Ruiz Salas V; Alegre M; Garcés JR; Puig L
Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
[TBL] [Abstract][Full Text] [Related]
23. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
24. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?
Zhu H; Lewis DJ
Expert Opin Pharmacother; 2022 Apr; 23(6):739-740. PubMed ID: 35258366
[TBL] [Abstract][Full Text] [Related]
25. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
26. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
27. [Vismodegib in metastasized basal cell carcinoma].
Reinders MG; Dirix L; Mosterd K; van Doorn R
Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
[TBL] [Abstract][Full Text] [Related]
28. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.
Kuonen F; Huskey NE; Shankar G; Jaju P; Whitson RJ; Rieger KE; Atwood SX; Sarin KY; Oro AE
J Invest Dermatol; 2019 Jul; 139(7):1439-1448. PubMed ID: 30707899
[TBL] [Abstract][Full Text] [Related]
29. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
30. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
Yin VT; Esmaeli B
Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
32. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
[TBL] [Abstract][Full Text] [Related]
33. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
34. Advanced treatment for basal cell carcinomas.
Atwood SX; Whitson RJ; Oro AE
Cold Spring Harb Perspect Med; 2014 Jul; 4(7):a013581. PubMed ID: 24985127
[TBL] [Abstract][Full Text] [Related]
35. Current landscape for treatment of advanced basal cell carcinoma.
Foley P
Australas J Dermatol; 2015 Mar; 56 Suppl 1():1-7. PubMed ID: 25715811
[TBL] [Abstract][Full Text] [Related]
36. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway.
Sekulic A; Mangold AR; Northfelt DW; LoRusso PM
Curr Opin Oncol; 2013 May; 25(3):218-23. PubMed ID: 23493193
[TBL] [Abstract][Full Text] [Related]
37. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
Collier NJ; Ali FR; Lear JT
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
[TBL] [Abstract][Full Text] [Related]
38. Basal cell carcinoma: a paradigm for targeted therapies.
Dreier J; Felderer L; Barysch M; Rozati S; Dummer R
Expert Opin Pharmacother; 2013 Jul; 14(10):1307-18. PubMed ID: 23656611
[TBL] [Abstract][Full Text] [Related]
39. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
40. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
